← Leaderboards
John A Copland
Mayo Clinic Jacksonville
$4,835,561
Attributed
$9,121,560
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,121,560 · 7
By mechanism
R01$3,968,654 · 3
R44$2,589,920 · 1
R42$2,000,000 · 1
R41$562,986 · 2
Top collaborators
- Kristopher Alan Kilian5 shared
- Robert Smallridge5 shared
- Karen E Hayes4 shared
- Winston Tan4 shared
- Karen Hayes2 shared
- Lori Hazlehurst1 shared
- Han W Tun1 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Robert Smallridge$778,663
- Nilufer Ertekin-Taner$28,054,444
- Lara M Mangravite$9,274,560
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorIn VivoSignal TransductionResponseMalignant NeoplasmsProteinsClinical TrialsCell LineLeadCombined Modality TherapyMediatingBaseCellsDrug ResistanceLinkPhenotypeGrowthTumorigenicMouse ModelIn VitroResistanceTargeted TreatmentNovel Therapeutic InterventionCell Proliferation
Grant awards (24)
Modulation of cancer induced immune suppression via inhibition of SCD1$217,685
R44 · FY2025 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$670,441
R44 · FY2024 · CA
Engineered microtumor arrays for development of combination therapies$106,589
R01 · FY2024 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$1,301,808
R44 · FY2023 · CA
Engineered microtumor arrays for development of combination therapies$145,949
R01 · FY2023 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$399,986
R44 · FY2022 · CA
Engineered microtumor arrays for development of combination therapies$260,106
R01 · FY2022 · CA
Engineered microtumor arrays for development of combination therapies$241,920
R01 · FY2021 · CA
Engineered microtumor arrays for development of combination therapies$243,896
R01 · FY2020 · CA
Novel SCD1 inhibitors for treatment of cancer$1,236,819
R42 · FY2019 · CA · contact PI
Novel SCD1 inhibitors for treatment of cancer$763,181
R42 · FY2018 · CA · contact PI
Osteopontin-targeted therapy for primary CNS lymphoma$283,986
R41 · FY2017 · CA · contact PI
Novel SCD1 inhibitors for treatment of cancer$279,000
R41 · FY2016 · CA
RhoB in cancer pathogenesis and as a target in combinatorial therapy$303,033
R01 · FY2014 · CA · contact PI
RhoB in cancer pathogenesis and as a target in combinatorial therapy$293,662
R01 · FY2013 · CA · contact PI
RhoB in cancer pathogenesis and as a target in combinatorial therapy$312,406
R01 · FY2012 · CA · contact PI
RhoB in cancer pathogenesis and as a target in combinatorial therapy$312,406
R01 · FY2011 · CA · contact PI
RhoB in cancer pathogenesis and as a target in combinatorial therapy$335,818
R01 · FY2010 · CA · contact PI
TGF Beta receptor biology in human renal cell carcinoma$152,867
R01 · FY2009 · CA · contact PI
TGF Beta receptor biology in human renal cell carcinoma$228,938
R01 · FY2008 · CA · contact PI
TGF Beta receptor biology in human renal cell carcinoma$230,760
R01 · FY2007 · CA · contact PI
TGF Beta receptor biology in human renal cell carcinoma$241,071
R01 · FY2006 · CA · contact PI
TGF Beta receptor biology in human renal cell carcinoma$252,483
R01 · FY2005 · CA
TGF Beta receptor biology in human renal cell carcinoma$306,750
R01 · FY2004 · CA